UCB SA (OTCMKTS:UCBJF) Receives $113.71 Consensus PT from Analysts

Shares of UCB SA (OTCMKTS:UCBJFGet Rating) have been assigned an average rating of “Buy” from the ten brokerages that are currently covering the firm, Marketbeat reports. Four research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 12 month price objective among analysts that have covered the stock in the last year is $113.71.

A number of equities analysts have recently commented on the company. Zacks Investment Research lowered UCB from a “buy” rating to a “hold” rating in a research note on Thursday, April 28th. UBS Group upgraded UCB from a “sell” rating to a “neutral” rating and set a $105.00 price objective on the stock in a research note on Wednesday, March 23rd. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a $95.00 price objective on shares of UCB in a research note on Friday. Finally, Cowen initiated coverage on UCB in a research note on Friday, January 21st. They set an “outperform” rating on the stock.

Shares of OTCMKTS:UCBJF traded up $1.25 on Tuesday, reaching $92.18. The company had a trading volume of 199 shares, compared to its average volume of 40. UCB has a twelve month low of $90.93 and a twelve month high of $122.90. The stock has a 50-day moving average price of $115.45 and a 200 day moving average price of $111.55. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.31 and a quick ratio of 1.00.

About UCB (Get Rating)

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.

Read More

Analyst Recommendations for UCB (OTCMKTS:UCBJF)

Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.